Discover investment opportunities in Genomics Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Genomics Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Genomics Stocks using our Smart AI Filter.
8 stocks found for "Genomics Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.92 | ±45.4% | -143.2 | 0.00% | |||
1.65 | ±68.2% | -10.2 | 0.00% | |||
1.19 | ±53.7% | -156.9 | 0.00% | |||
3.05 | ±100.0% | -2.4 | 0.00% | |||
1.82 | ±67.7% | -15.1 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
1.19 | ±46.0% | -133.7 | 0.00% | |||
0.89 | ±41.9% | 22.8 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What opportunities do genomics stocks like ILMN and CRSP present for growth investors?
A: Genomics stocks such as ILMN (Illumina) and CRSP (CRISPR Therapeutics) are at the forefront of genetic research and personalized medicine, offering high growth potential. Their role in advancing gene-editing technologies and DNA sequencing may drive future revenue, although these opportunities come with significant research and development expenses.
Q: How does the volatility of NTLA compare to other genomics stocks?
A: NTLA (Intellia Therapeutics) shows typical volatility for mid-cap biotech firms, often influenced by clinical trial results and regulatory news. This volatility can offer both risk and reward, so investors in NTLA should consider potential price swings in comparison to other genomics stocks like NVTA.
Q: What are some sector-specific risks associated with investing in companies like EXAS and PACB?
A: Companies like EXAS (Exact Sciences) and PACB (Pacific Biosciences) face risks including high R&D costs, regulatory hurdles, and rapid technological change. As genomics technology evolves, these firms must continually innovate to maintain competitive market positions.
Q: Can investors expect consistent dividends from companies such as QGEN and NSTG?
A: Generally, genomics companies including QGEN (Qiagen) and NSTG (NanoString Technologies) do not prioritize dividend payments as they reinvest earnings into R&D. Investors seeking income may find more reliable dividends in other sectors.
Q: How does NVTA’s financial health impact its investment appeal?
A: NVTA (Invitae Corporation) has pursued aggressive growth, leading to mixed financial metrics with a negative operating cash flow and high debt levels. While promising future growth, this may concern risk-averse investors who prioritize near-term financial stability.
Q: Why might TWST be a strategic addition for an ESG-focused investor?
A: TWST (Twist Bioscience) emphasizes sustainable practices in synthesizing DNA using innovative technology. This may attract ESG-focused investors looking for companies with environmentally-friendly business models and a commitment to reducing ecological impacts.
The heavy selling pressure might have exhausted for Twist Bioscience (TWST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read more